

## **BRAVACCINI SARA *PhD* (18/07/1975)**

### **Curriculum Vitae**

- 2001: Degree in Medical Biotechnology from the University of Bologna (102/110)
- 2009: Second Degree in Molecular and Cellular Biology (110/110 cum Laude)
- 2010: State exam to qualify as professional biologist
- 2014: PHD in Medicine (Nephro-UroAndrology)

### **PROFESSIONAL WORK EXPERIENCE**

#### **Post-graduate**

- 2001-2007: Researcher at the Biological Laboratory of Morgagni-Pierantoni Hospital, Forlì
- 2008-2014: Full-time biotechnologist (now Senior Researcher) with the same group, which has now moved to Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l.(Meldola, FC)

#### **Other CV information:**

Coordinator of the Cyto-Histo-Molecular Pathology research group at I.R.S.T.

Presenter of several oral communications and posters

Lead researcher in several projects on breast cancer biomolecular characterization

More than 25 published articles

More than 10 years of experience in cancer research and molecular diagnosis

Member of the University of Bologna Examination Board

Reviewer for several scientific journals (Int J Cancer, Cell Oncol, Clin Chem Acta)

Editorial Board member of Journal of Urology

Member of the European Cell Proliferation Society (ECPS) AACR, SIUrO (Italian Society of Uro-Oncology)

#### **Principal investigator in the following research projects:**

- Characterization of new MoAb directed against human telomerase reverse transcriptase (hTERT) in cancer cell lines and tissue
- Role of telomerase in cervical and bladder cancer
- Diagnostic, prognostic and predictive role of breast cancer biomarkers

## **ORAL PRESENTATIONS**

Core curriculum Uro-Oncol. Clinical application of Bladder cancer biological markers Bertinoro, FC mar 2011

13 th course: advances in urological Oncology. Tissue, blood, urine biomarkers Erice Sicily, apr 2011

XXI Congress SIURO Naples jun 2011 a)Contribution of TRAP and FISH approaches to increase diagnostic accuracy of bladder cancer in symptomatic patients b) Significance of telomerase

Usefulness of biomarkers in the detection of bladder cancer in the clinical practice IRST Meldola, FC jun 2012

“Dosser Study” Preliminary results Bologna apr 2012

FISH Role in the clinical practice 22° SIURO Bologna jun 2012

Non Invasive, early diagnosis of superficial bladder cancer: urine cell free Dna integrity and cytology 22° SIURO Bologna jun 2012

Investigator’s Meeting IRST 174.08 “A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy IRST Meldola FC mar 2013

Biomarkers of aggressiveness and evolution in in-situ breast cancer IRST Meldola FC mar 2013

Usefulness of biomarkers in the detections of bladder cancer in the clinical practice Lisbon, Portugal 9-11 sep 2013

## **Moderator at the following meetings**

Male Breast Cancer at the Medical Congress ‘Malattie Rare’, Forlì, Dec 2010

Oral communication on kidney cancer, 2 SIURO, Naples, Jun 2011

Meet the authors poster session II group at 22<sup>nd</sup> SIURO Congress, Bologna, Jun 2012

## **AWARDS**

5 grants awarded during the course of her studies

The poster “*Characterization of a panel of cell lines and tissue with a new anti hTERT monoclonal antibody,*” (S. Bravaccini et al) presented at AACR Annual Meeting, S Francisco, USA, 3-7 Nov 2004, won the “Geron Corporation” award.

The project “*Studio di marcatori predittivi di risposta alla terapia adiuvante nei pazienti con carcinoma della mammella ad alta proliferazione (Studio IBIS3)*” S Bravaccini, et al won an award from Istituto Oncologico Romagnolo (IOR) in 2009.

My oral presentation “*Non Invasive, early diagnosis of superficial bladder cancer: urine cell free DNA integrity and cytology*” at the 22<sup>nd</sup> Urological National Congress in Bologna, June 2012, won the Rocchetta Award as one of the 5 best scientific contributions.

### **Selection of 10 papers:**

1. **S. Bravaccini**, M. M. Tumedei, E. Scarpi, W. Zoli, C. Rengucci, L. Serra, A. Curcio, F. Buggi, S. Folli, A. Rocca, R. Maltoni, M. Puccetti, D. Amadori, and R. Silvestrini New Biomarkers to Predict the Evolution of *In Situ* Breast Cancers. Volume 2014, Article ID 159765. IF 2.88.
- 2.A. Rocca, A. Farolfi, **S. Bravaccini**, A. Schirone, D. Amadori. Palbociclib (PD 0332991):Targeting the cell cycle machinery in breast cancer Expert Opinion on Pharmacotherapy. 2014;15(3):407-420. IF 4.431.
3. A. Rocca, **S. Bravaccini**, E. Scarpi, A. Mangia, S. Petroni, M. Puccetti, L. Medri, L. Serra, M. Ricci, S. Cerasoli, N. Biglia, R. Maltoni, DC. Giunchi, L. Gianni, A. Tienghi, M. Brandi, M. Faedi, P. Sismondi, A. Paradiso, R. Silvestrini, D. Amadori. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Research and Treatment. 2014;144(2):307-318. IF 4.431.
4. D. Amadori, P. Serra, **S. Bravaccini**, A. Farolfi, M. Puccetti, E. Carretta, L. Medri, O. Nanni, MM. Tumedei, J. Kahima, N. Masalu. Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations Breast Cancer Research and Treatment. 2014;145(1):177-183. IF 4.431.
5. **S. Bravaccini**, A. M. Granato, L. Medri, F. Foca, F. Falcini, W. Zoli, M. Ricci, G. Lanzanova, N. Masalu, L. Serra, F. Buggi, S. Folli, R. Silvestrini, D. Amadori. Biofunctional characteristics of in situ and invasive breast carcinoma. Cellular Oncology. 2013;36(4):303-310. IF 3.105.
6. **S. Bravaccini**, C. Rengucci, L. Medri, W. Zoli, R. Silvestrini, D. Amadori. Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches Journal of Clinical Pathology. 2012;65(2):183-185. IF 2.306.
7. **S. Bravaccini**, V. Casadio, R. Gunelli, L. Bucchi, W. Zoli, D. Amadori, R. Silvestrini, D. Calistri. Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients Annals of Oncology. 2011;22(10):2294-2298. IF 6.425.
8. **S. Bravaccini**, M. A. Sanchini, A. M. Granato, R. Gunelli, O. Nanni, D. Amadori, D. Calistri, R. Silvestrini. Urine Telomerase Activity for the Detection of Bladder Cancer in Females. Journal of Urology. 2007;178(1):57-61. IF 3.746.
9. M. A. Sanchini, R. Gunelli, O. Nanni, **S. Bravaccini**, C. Fabbri, A. Sermasi, E. Bercovich, A. Ravaioli, D. Amadori, D. Calistri. Relevance of urine telomerase in the diagnosis of bladder cancer. Journal of the American Medical Association. 2005;294(16):2052-2056. IF 30.026.
10. **S. Bravaccini**, M.A. Sanchini, A. Amadori, L. Medri, L. Saragoni, D. Calistri, F. Monti, A. Volpi, D. Amadori. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool Journal of Clinical Pathology. 2005;58(9):911-914. IF 2.306.